Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary Angioplasty
- 1 March 1995
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 91 (5) , 1427-1431
- https://doi.org/10.1161/01.cir.91.5.1427
Abstract
Background Elevated levels of shear stress such as those that occur in stenotic arterial vessels can directly activate and aggregate platelets and thus contribute to the pathogenesis of acute arterial thrombosis. This shear-induced platelet aggregation (SIPA) is mediated by von Willebrand factor binding to platelet membrane glycoprotein (GP) Ib and GPIIb/IIIa. The chimeric Fab fragment of the monoclonal antibody 7E3 (c7E3 Fab) that binds selectively to GPIIb/IIIa is under clinical evaluation in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). This study was undertaken to investigate the effects on ex vivo SIPA of c7E3 Fab administered to patients undergoing PTCA. Methods and Results Six patients received aspirin (325 mg) and boluses of heparin (12 000 U) followed by c7E3 Fab 0.25 mg/kg. Blood collected from each patient before and after heparin treatment and at various time points after c7E3 Fab administration was subjected to laminar shear stress in a cone-and-plate viscometer. Flow cytometry was used to quantify the extents of platelet aggregation and of antibody binding to GPIIb/IIIa. Results indicate that c7E3 Fab injection resulted in a rapid, extensive blockade of GPIIb/IIIa receptors (98.6±0.2%) and a 50% inhibition of ex vivo platelet aggregation induced by shear stress. c7E3 Fab also completely abolished the formation of large platelet aggregates (“large” refers to particles >10 μm in equivalent sphere diameter), which are presumably the aggregates of greatest clinical significance. Partial reversibility of the inhibition was noted within 2 days after drug administration, but even after 1 week, platelet function had not been fully restored. Conclusions This study demonstrates that c7E3 Fab is a potent inhibitor of SIPA, which may be an important mechanism of its beneficial effect in the treatment of arterial occlusive diseases and in the prevention of thrombotic complications of coronary artery disease after angioplasty.Keywords
This publication has 20 references indexed in Scilit:
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot studyJournal of the American College of Cardiology, 1993
- The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.Journal of Clinical Investigation, 1991
- Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.Journal of Clinical Investigation, 1990
- Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplastyAmerican Heart Journal, 1989
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplastyThe American Journal of Cardiology, 1987
- Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.Journal of Clinical Investigation, 1986
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.Journal of Clinical Investigation, 1985
- Analysis of pulsatile, viscous blood flow through diseased coronary arteries of manJournal of Biomechanics, 1977